Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
Andre Goy
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Vincent Ribrag
Honoraria - Celgene
Research Funding - Celgene
Andrea Varga
No relevant relationships to disclose
Thomas E. Witzig
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Enrique M. Ocio
Honoraria - Celgene
Research Funding - Celgene
Luis G. Paz-Ares
Research Funding - Celgene
Monica M. Mita
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Tim Meyer
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Pamela N. Munster
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Amit Mahipal
Research Funding - Celgene
Jean-Pierre Delord
Research Funding - Celgene
Hendrik-Tobias Arkenau
Research Funding - Celgene
Martin Gutierrez
No relevant relationships to disclose
Angela James
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Lilly Wong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shuichan Xu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Xiaoling Wu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
James Carmichael
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kristen Hege
Employment or Leadership Position - Celgene
Stock Ownership - Celgene